Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection
about
Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directionsHelicobacter pylori vaccination: is there a path to protection?Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patchImmunology of Gut Mucosal VaccinesEvaluation of combinatorial vaccines against anthrax and plague in a murine modelToward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized MiceTherapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy.Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model.Transfer of antigen-pulsed dendritic cells induces specific T-Cell proliferation and a therapeutic effect against long-term Helicobacter pylori infection in mice.Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates.The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigensColonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunityHelicobacter pylori inflammation and immunity.Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection.Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pyloriHuman immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods.Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G.Survey of human-use adjuvants.Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin.Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis.Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.Construction of hpaA gene from a clinical isolate of Helicobacter pylori and identification of fusion protein.L-forms of H. pyloriHelicobacter pylori L-form and patients with chronic gastritisConstruction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins.Leptin, CD4(+) T(reg) and the prospects for vaccination against H. pylori infection.Protective immunity against Helicobacter is characterized by a unique transcriptional signatureEffects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice.The current status of Helicobacter pylori vaccines: a review.Progress in vaccine development against Helicobacter pylori.A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
P2860
Q26778023-5E1FACFD-46EB-448C-9AD5-5E29D78BA57CQ26865279-F1CACBE0-E3CA-495E-8AC4-CF414CD76FA2Q28252883-19927684-9FB2-4A48-84BF-89EC23085A63Q28972559-D00D9493-31B5-4961-A2B5-C7FEB211FBD0Q33283821-B1DB804C-09D4-4F46-9BCB-FABE8F0398C2Q33624306-1DCA84C3-A915-497A-8B3B-D8BC2F2FCFD5Q33787778-281B8872-F27A-4B96-B718-73965EC4E656Q33946563-DA185593-F727-427F-ABCB-5C38D15F911DQ34124621-02C91D64-7E70-4A55-9D84-5D5F87DD87EEQ34143589-1C1473FA-5E72-4BB7-8965-163FAC010804Q34186333-5E7567F6-3AE9-41CD-8D85-71552503691DQ34268349-F45367F9-A99E-4F5A-A5AD-054CC005AA03Q34334248-70D21E1C-9D39-46F6-8EDD-A12F3E6D544DQ34403586-D43044C0-41BA-4A03-B7BD-32EC85FEBA4DQ34531903-7F57CE4B-3A15-4374-9DD9-B8424777035EQ34532223-F7B59140-D453-4849-917B-084DF1FDA9EBQ34582242-DD282A32-4049-4139-ABD0-80B151216BCBQ34799570-906D4CE7-15F1-422A-82AA-94539D591D7DQ34837506-13859782-EF87-40B5-80EB-D530C900851EQ35066293-BBE6ED6A-16A4-402D-B860-D67224FE10F8Q35104855-D83C4D2D-21D4-46C1-8BE7-8B952D0E5FFCQ35150416-13E8BFB1-DA2E-401B-9871-CEBB361FD160Q35155937-2D7C1E74-DDB6-4C77-B0F8-8C4A007393C9Q35192171-9D5C408F-8C4B-494A-A02E-5446F682EB0CQ35192195-CDB17930-8132-4F29-97FA-50ABB91E35A2Q35192203-35175D28-476E-47DB-9493-324187A7D86AQ35550167-26B34381-78AC-4FB1-A1BC-515D3A19C980Q35833473-4D37FD57-0651-4B39-9D7C-59A165E88B06Q36178924-6C39486B-11BE-46BD-99F7-498A320CE37CQ36190700-E8E67646-4A08-4A1F-9781-F27C5B600B07Q36209731-EC6685B7-0817-47CF-A092-5E922BB949D9Q36213815-C1647FE4-68F2-4971-AC87-45F7557A8B1EQ36308682-8E769CA1-51EF-40C3-AA07-0F7E1E7A699FQ36316310-7EBB55F6-C43B-406A-8865-74831CBA6192Q36349622-CD410882-6736-426F-A19B-875FD59EBB16Q36447506-DA84E2F5-3ECC-4847-A62B-423E8E7AFD9DQ36740010-773251A4-F4FF-4E11-9616-6B3FE5AE9107Q36794861-CEEF41BF-B4F5-412F-B83E-C46E32CF8487Q36826907-42556BC7-F7C9-496F-BCC2-9D4360D93BEFQ36844890-7D399D82-86A1-4A02-A60B-437FA8768271
P2860
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety and immunogenicity of o ...... without subclinical infection
@ast
Safety and immunogenicity of o ...... without subclinical infection
@en
Safety and immunogenicity of o ...... without subclinical infection
@nl
type
label
Safety and immunogenicity of o ...... without subclinical infection
@ast
Safety and immunogenicity of o ...... without subclinical infection
@en
Safety and immunogenicity of o ...... without subclinical infection
@nl
prefLabel
Safety and immunogenicity of o ...... without subclinical infection
@ast
Safety and immunogenicity of o ...... without subclinical infection
@en
Safety and immunogenicity of o ...... without subclinical infection
@nl
P2093
P2860
P1476
Safety and immunogenicity of o ...... without subclinical infection
@en
P2093
DiLorenzo SC
Kotloff KL
Losonsky GA
Wasserman SS
P2860
P304
P356
10.1128/IAI.69.6.3581-3590.2001
P407
P577
2001-06-01T00:00:00Z